Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.2481 | 0.4766 | 0.7442 |
Echinococcus granulosus | integrin alpha 3 | 0.2514 | 0.4834 | 1 |
Schistosoma mansoni | integrin alpha | 0.3279 | 0.639 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0705 | 0.1157 | 0.1157 |
Loa Loa (eye worm) | hypothetical protein | 0.1809 | 0.3402 | 0.3402 |
Echinococcus multilocularis | integrin alpha ps | 0.147 | 0.2712 | 0.5573 |
Loa Loa (eye worm) | hypothetical protein | 0.0765 | 0.128 | 0.128 |
Echinococcus multilocularis | integrin alpha ps | 0.147 | 0.2712 | 0.5573 |
Brugia malayi | Integrin beta pat-3 precursor | 0.0804 | 0.1358 | 0.2073 |
Schistosoma mansoni | integrin alpha-ps | 0.0765 | 0.128 | 0.1913 |
Schistosoma mansoni | hypothetical protein | 0.0705 | 0.1157 | 0.1718 |
Loa Loa (eye worm) | hypothetical protein | 0.2481 | 0.4766 | 0.4766 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0146 | 0.0021 | 0.5 |
Echinococcus multilocularis | integrin alpha 3 | 0.2514 | 0.4834 | 1 |
Echinococcus multilocularis | integrin alpha ps | 0.0705 | 0.1157 | 0.2326 |
Echinococcus granulosus | integrin alpha ps | 0.0705 | 0.1157 | 0.2326 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0146 | 0.0021 | 0.5 |
Schistosoma mansoni | integrin beta subunit | 0.0473 | 0.0686 | 0.0973 |
Echinococcus granulosus | integrin alpha ps | 0.147 | 0.2712 | 0.5573 |
Loa Loa (eye worm) | integrin beta-2 | 0.0804 | 0.1358 | 0.1358 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.3279 | 0.639 | 1 |
Schistosoma mansoni | integrin alpha-ps | 0.147 | 0.2712 | 0.418 |
Echinococcus granulosus | integrin beta 2 | 0.0595 | 0.0934 | 0.1862 |
Echinococcus multilocularis | integrin beta 2 | 0.0595 | 0.0934 | 0.1862 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0156 | 0.0042 | 0.0042 |
Loa Loa (eye worm) | hypothetical protein | 0.2575 | 0.4958 | 0.4958 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.1689 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 125.8925 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488939] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.